GenBioPro stock rises on mifepristone access ruling

Market overview

GenBioPro, a manufacturer of generic mifepristone, will see a 15% or greater increase in its stock price within 30 days of a Supreme Court decision that permanently blocks restrictions on mifepristone access. The ruling validates the company's business model and removes regulatory uncertainty.

price prediction market

Implied probability (Yes)

60%

Source: user-generated

More price markets

• Aluminum price exceeds $2,800/ton by year-end — 65% Yes
• Even Realities stock valuation increases by 15% within 6 months of G2 launch — 50% Yes
• CrowdStrike stock rises above $300 by 2026-11-10 — 70% Yes
• Meta’s ad-free Instagram plan gains 5M+ U.S. subscribers by 2026-08-31 — 68% Yes
• Oil prices to surge past $90/barrel by mid-2026 due to Middle East disruptions — 65% Yes
• Pharmaceutical stocks drop 10% if Trump plan gains traction — 70% Yes
• Starbucks increases coffee prices 10% globally by Nov 2026 — 70% Yes
• Stocks of major private prison companies rise 20% by 2026 due to crime rate predictions — 65% Yes

Browse all price markets →